Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts. Previous reviews discussed herb–drug interactions and asthma phytotherapy separately. There is no combined pharmacokinetic, pharmacodynamic, and toxicological evidence for all modern anti‐asthma agents. This review closes that gap. It draws from mechanistic, preclinical, and clinical data. It looks at eight common botanicals: Glycyrrhiza glabra , Curcuma longa , Nigella sativa , Boswellia serrata , Tylophora indica , Adhatoda vasica , Astragalus membranaceus , and Piper nigrum . The review explains how these botanicals affect cytochrome P450 isoenzymes, Phase II conjugative enzymes, and membrane transporters, including P‐glycoprotein. It also considers shared adrenergic, glucocorticoid‐receptor, and inflammatory targets of inhaled corticosteroids, β 2 ‐agonists, leukotriene receptor antagonists, theophylline, and biologic agents. These interactions create clinical hazards. For example, Hypericum perforatum increases CYP3A4 activity by up to 11‐fold and can destabilize theophylline and corticosteroid levels. Ephedra sinica causes dose‐dependent sympathomimetic toxicity, which worsens β 2 ‐agonist cardiovascular risk. Glycyrrhiza glabra may trigger pseudoaldosteronism and hypokalaemia by inhibiting 11β‐hydroxysteroid dehydrogenase type 2. Ginkgo biloba has been tied to bleeding events. Turmeric, previously seen as safe, now appears in drug‐induced liver injury registries. Compositional variability adds to the risk; for example, hyperforin content can range from 0.01% to 1.89%, and ephedrine content varies by more than 12‐fold across products. This review places its findings in the context of the WHO Global Traditional Medicine Strategy 2025–2034. It identifies important herb–anti‐asthma drug pairs, defines monitoring endpoints, and proposes a pharmacogenetically informed framework for safely integrating medicinal plants into asthma care.